Botanix Pharmaceuticals logo

Botanix Pharmaceuticals(ASX) BOT

Market CapA$38.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-53%
5 Year-79%
1 Year-91%
1 Month-30%
A$0.01
-6.67%
-0.00Today
Botanix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.012026-10-09
Botanix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-22.22%AUD 0.022026-10-02
1 month-30%AUD 0.022026-09-09
3 month-41.67%AUD 0.022026-07-10
Year to date-89.63%AUD 0.142025-12-31
1 year-91.25%AUD 0.162025-10-09
3 year-90%AUD 0.142023-10-10
5 year-79.1%AUD 0.072021-10-08
Since inception-53.33%AUD 0.032016-07-15

Botanix Pharmaceuticals Financials at a Glance

Market Cap

A$38.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$40.30M

Net Income (TTM)

-A$156.16M

EPS (TTM)

-A$0.03

P/E Ratio

-0.43

Dividend

A$0.00

Beta (Volatility)

-0.05 (Low)

Price

A$0.01

Volume

5,027,955

Open

A$0.02

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.02

52-Week Range

A$0.01 - A$0.17

Estimated Earnings Date

Mar 3, 2027

BOT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited is an Australian biotechnology company focused on developing innovative dermatological and antimicrobial therapeutic agents. The company aims to address common skin conditions and infections through its advanced product pipeline.

Products and Services
  • Sofpironium Bromide for primary axillary hyperhidrosis
  • BTX 1503, a transdermal gel for severe acne
  • BTX 1801 targeting Staphylococcus aureus infections
Growth Outlook
  • Successful Phase 3 trials for Sofpironium Bromide enhance market potential
  • BTX 1503 completed Phase II trials, indicating strong product viability
  • Expansion into atopic dermatitis with BTX 1204A shows strategic growth
Financial Highlights
  • Recent quarterly revenue of AUD 18,007,072 reflects significant growth
  • Cash reserves of AUD 36,631,217 support ongoing research and development
  • Current ratio of 2.59 indicates strong liquidity position
Botanix Pharmaceuticals Limited operates with a clear focus on addressing unmet medical needs in dermatology and infectious diseases. The company's robust pipeline, including products that have reached advanced clinical stages, positions it well for future growth. Recent financial performance highlights, including a notable increase in quarterly revenue and a solid cash position, further underscore the company's potential for sustained development. With a commitment to innovation and a strategic approach to market entry, Botanix Pharmaceuticals is poised to make a significant impact in the healthcare sector.
AI Generated • Sep 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

33

CEO

Howie McKibbon, PharmD

Website

www.botanixpharma.com

Headquarters

Melbourne, VIC 3008, AU

BOT Financials

Key Financial Metrics (TTM)

Gross Margin

-172.20%

Operating Margin

-200.82%

Net Income Margin

-202.15%

Return on Equity

-118.74%

Return on Capital

-88.56%

Return on Assets

-65.83%

Earnings Yield

-2.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$38.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.76B

Volume

5.03M

Avg. Volume

7.39M

Financials (TTM)

Gross Profit

-A$57.41M

Operating Income

-A$151.12M

EBITDA

-A$148.77M

Operating Cash Flow

-A$143.18M

Capital Expenditure

-A$286.43K

Free Cash Flow

-A$143.47M

Cash & ST Invst.

A$36.63M

Total Debt

A$14.74M

Botanix Pharmaceuticals Performance Analysis

Botanix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 914,973N/A
20242024-06-30AUD 1,034,55813.1%
20252025-06-30AUD 6,482,824526.6%
20262026-06-30AUD 34,512,897432.4%
Botanix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-77.7%
Q42025-06-301333.2%
Q22025-12-31205.0%
Q42026-06-309.1%
Botanix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-41.5%
20242024-06-30AUD -0.0116.5%
20252025-06-30AUD -0.05408.7%
20262026-06-30AUD -0.03-31.2%
Botanix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-214.8%
Q42025-06-30-74.1%
Q22025-12-3142.9%
Q42026-06-309.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$18.01M

+964.2%

Gross Profit

-A$30.67M

-3023.2%

Gross Margin

-1.70%

N/A

Market Cap

A$38.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$3.51M

N/A

Employees

11

N/A

Net Income

-A$36.57M

-335.2%

EBITDA

-A$35.69M

-324.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$36.63M

-53.8%

Total Debt

A$14.74M

N/A

Accounts Receivable

A$6.64M

+712.8%

Inventory

A$31.35M

+2492.3%

Long Term Debt

A$448.66K

N/A

Short Term Debt

A$14.29M

N/A

Return on Assets

-65.83%

N/A

Return on Invested Capital

-92.42%

N/A

Free Cash Flow

-A$31.95M

-619.1%

Operating Cash Flow

-A$31.96M

-631.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATH.AXAlterity Therapeutics Limited
A$0.36-2.74%
RCE.AXRecce Pharmaceuticals Ltd
A$0.30+3.51%
NYR.AXNyrada Inc.
A$0.48-2.04%
DXB.AXDimerix Limited
A$0.22+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About BOT

What is the current price of Botanix Pharmaceuticals?

Botanix Pharmaceuticals is trading at A$0.01 per share.

What is the 52-week range for Botanix Pharmaceuticals?

Over the past 52 weeks, Botanix Pharmaceuticals has traded between A$0.01 and A$0.17.

How much debt does Botanix Pharmaceuticals have?

As of the most recent reporting period, Botanix Pharmaceuticals reported total debt of A$25.77M.

How much cash does Botanix Pharmaceuticals have on hand?

Botanix Pharmaceuticals reported A$36.63M in cash and cash equivalents in its most recent financial results.

What is Botanix Pharmaceuticals’s dividend yield?

Botanix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services